Dr William Makis’ Cancer Protocols

These are Dr William Makis’ cancer protocols. You can find out more about them here and a very recent list of studies that support them here.

Dr Makis proposes four distinct experimental protocols for using Ivermectin in cancer treatment, specifically for patients who have developed turbo cancer, the aggressive cancers observed in COVID-19 mRNA vaccinated individuals. These protocols, referred to as the “Dr. Makis Ivermectin Cancer Protocols,” are categorized based on dosage and the severity of the cancer.

While these have been developed due to necessity after the explosion in cancers due injection of the poison, unvaccinated individuals and those who had cancer prior to the rollout can also benefit from these methods.

The Low Dose Protocol (≤0.5 mg/kg) is recommended for patients with cancers in remission, those with a strong family history of cancer, or individuals with a genetic predisposition. It can also be considered for prophylactic use to potentially reduce cancer risks.

This is similar to the dosage that we here at FirstMed Inc. were using to treat patients prior to learning about Dr Makis’ work. We have been combining this with the use of cannabis oil – which is legal here – and apricot kernels and have been having quite a lot of success with this.

We are now however testing Dr Makis’ more aggressive protocols to assist patients in their healing are recovery in a shorted time frame.

The Medium Dose Protocol (1.0 mg/kg) serves as a starting point for most cancers, including mRNA vaccine-induced turbo cancers such as lymphoma, breast cancer, colon cancer, lung cancer, melanoma, and testicular, cervical, ovarian, or kidney cancers. This dosage is suitable for newly diagnosed cases requiring immediate intervention.

The High Dose Protocol (2.0 mg/kg) is suggested for aggressive turbo cancers, particularly leukemias, pancreatic cancer, and brain tumors. The aggressiveness of a tumor can often be determined by pathology reports, such as Ki67 staining levels exceeding 80 percent. This protocol also applies to rare, highly aggressive cancers like appendix cancer, gallbladder cancer, cholangiocarcinoma, angiosarcoma, and other sarcomas.

The Very High Dose Protocol (2.5 mg/kg) is reserved for desperate cases, where patients have only days to live or are experiencing extreme tumor metastases with a poor prognosis. It may also be applicable to certain aggressive or very large brain tumors, where traditional treatment options are limited.

These protocols offer a tiered approach to incorporating Ivermectin into cancer treatment plans, addressing varying levels of disease severity and providing a potential option for patients with limited treatment choices.

Examples of Which Protocol to Choose

Consider the following real-world scenarios to better understand how Ivermectin can be used as an adjunct treatment for various cancers, particularly in individuals who have received multiple COVID-19 mRNA vaccines.

In one case, a 30-year-old teacher weighing 60 kg, who took four doses of Pfizer or Moderna COVID-19 vaccines, is diagnosed with Stage 4 Turbo Colon Cancer with liver metastases — a pattern that has become alarmingly common in recent months. Alongside their standard chemotherapy and radiation treatments, they decide to try a medium-dose regimen of Ivermectin at 1 mg/kg/day, which amounts to 60 mg of ivermectin daily.

In tablet form, this equates to five 12 mg tablets each day. The cost of the pills from us for this treatment works out to $11.50 per day. Despite the cost, most patients are willing to make this investment, particularly when facing late-stage cancer with limited conventional treatment options.

N.B. We do not encourage or believe that chemo/radiation therapy is necessary, the above is Dr William Makis’ direct example.

Let’s explore another scenario. A 25-year-old individual, who received three doses of COVID-19 mRNA vaccines and has a strong family history of cancer, is increasingly concerned about the possibility of developing Turbo Cancer. As a precaution, she decides to follow a low-dose prophylactic regimen, taking 12 mg of Ivermectin daily — equivalent to one 12 mg tablet per day. While there are no human clinical trials currently examining Ivermectin as a cancer prevention method, some patients take this step out of a desire to reduce perceived risks.

Now, consider a more severe case. A 45-year-old Canadian doctor, who took eight doses of COVID-19 mRNA vaccines, is diagnosed with a Grade 4 glioblastoma, a highly aggressive brain tumor the size of a baseball. Given only weeks to live, he opts for a very high-dose regimen of 2.5 mg/kg/day — which amounts to 12 tablets of 12 mg each day. After starting this regimen, he experiences temporary visual disturbances, a known side effect at higher doses, which resolves within a few days. Over the next several weeks, his tumor begins to shrink in size, leaving his colleagues baffled by the unexpected improvement.

For brain cancers, particularly glioblastomas, the challenge lies in getting sufficient amounts of Ivermectin to cross the blood-brain barrier to exert its effects on the tumor. This is why higher doses are often necessary in these cases. Patients and doctors alike are beginning to explore these off-label uses of ivermectin as part of a broader cancer treatment strategy, despite the absence of formal clinical guidelines.

We have personal experience in attempting to treat glioblastoma with a lower dose of Ivermectin which wasn’t sufficient to penetrate the blood-brain barrier and resulted in the only cancer patient we have lost. We wish we had known about Dr William’s work sooner so we could have saved you too, Leo. RIP.